News

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study to Investigate the T Cell Response to SARS-CoV-2 Infection
Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunological Response to SARS-CoV-2 Infection in Patients with Primary and Secondary Antibody Deficiency
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study

Page: 1 2 3 … 21 Next